Amgen, the $100 billion biotech giant based in Thousand Oaks, announced an all-cash offer May 22 to acquire Copenhagen-based research institute Nuevolution for $167 million. At $3.37 per share, the offer nearly triples the value of the stock, which closed May 21 at 12.1 Swedish krona, or $1.26 per share, on the Nasdaq Stockholm exchange.…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
